# CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

> **NCT06696846** · PHASE1 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 25 (estimated)

## Conditions studied

- Relapsed/Refractory T-cell Lymphoma
- Relapsed/Refractory Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CD70 CAR-NK

## Key facts

- **NCT ID:** NCT06696846
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696846, "CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06696846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*